AstraZeneca Admits To Mistakes In Coronavirus Vaccine Trial

AstraZeneca, in collaboration with the University of Oxford, conducted a COVID-19 vaccine trial. The vaccine showed 90% efficacy with 1.5 doses but only 62% with two full doses. A manufacturing issue led to some vials having lower concentrations, which has been corrected. The trial results will be reviewed by UK regulators for potential approval.

What was the effectiveness of AstraZeneca's vaccine when participants received 1 1/2 doses?

• 62%

• 70%

• 90%

• 50%

How effective was the vaccine when two full doses were administered?

• 62%

• 85%

• 90%

• 75%

What issue did Oxford University acknowledge regarding the vaccine trial?

• Incorrect participant data

• Lower concentration in some vials

• Expired vaccine doses

• Inadequate trial size

What action was taken to address the manufacturing problem?

• The trial was halted

• The issue was discussed with regulators

• Participants were given additional doses

• The vaccine formula was changed

What is the next step for the trial results according to the transcript?

• To be presented at a conference

• To be sent to UK regulators

• To be shared with the public

• To be published in a scientific journal